Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142129 · ClinicalTrials.gov registry record · Phase 2
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
A Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 2
- Study locations
NCT00142129: Completed Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia, sponsored by Dana-Farber Cancer Institute.
NCT00142129 is a Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 27 participants, below the 107-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00142129, a Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate how tumors in patients with Waldenstrom's macroglobulinemia respond to treatment with bortezomib (Velcade) and to see what effects (good and bad) it has on the cancer.
Conditions Studied
Interventions
- DRUG Bortezomib (Velcade)
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Center - Boston
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2003-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00142129 record still lists
NCT00142129 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 107-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Lymphoplasmacytic Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Bortezomib (Velcade) is the first listed.
NCT00142129 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00142129 about?
NCT00142129 is a clinical study titled "Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia". The purpose of this study is to evaluate how tumors in patients with Waldenstrom's macroglobulinemia respond to treatment with bortezomib (Velcade) and to see what effects (good and bad) it has on the cancer.
What is the current status of trial NCT00142129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2003-12. Estimated completion is 2007-06.
What conditions does trial NCT00142129 study?
This clinical trial studies the following conditions: Lymphoplasmacytic Lymphoma, Waldenstrom's Macroglobulinemia.
What interventions are being tested in trial NCT00142129?
The interventions under investigation include: Bortezomib (Velcade) (DRUG).
Who is sponsoring clinical trial NCT00142129?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00142129 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoplasmacytic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00142129's enrollment target sits among peer trials
27 16th of 18 higher than 2 of 18 other Lymphoplasmacytic Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoplasmacytic Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
-
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia